Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled date : 2020 - 12 - 03 save search
Alnylam Completes Enrollment in ILLUMINATE-C Phase 3 Study of Lumasiran, an RNAi Therapeutic, for the Treatment of Advanced Primary Hyperoxaluria Type 1
Published: 2020-12-03 (Crawled : 16:00) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.41%
H: 2.21%
C: 0.9%
phase 3 treatment enroll
Iterum Therapeutics Announces Topline Results from its Phase 3 Clinical Trial of Oral Sulopenem for the Treatment of Uncomplicated Urinary Tract Infections
Published: 2020-06-29 (Crawled : 15:40) - globenewswire.com
ITRM | $1.52 -3.8% -3.95% 36K
|
Health Technology
|
| O: -4.58%
H: 0.68%
C: -2.74%
results phase 3 trial sulopenem treatment topline injection infections
Iterum Therapeutics Announces Positive Pre-NDA Meeting with FDA for Sulopenem for Treatment of Uncomplicated Urinary Tract Infections
Published: 2020-09-30 (Crawled : 15:40) - globenewswire.com
ITRM | $1.52 -3.8% -3.95% 36K
|
Health Technology
|
| O: 155.13%
H: 48.78%
C: -35.98%
positive fda sulopenem treatment injection infections
Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease
Published: 2020-12-03 (Crawled : 15:01) - globenewswire.com
AKTX | $1.25 3.31% 3.2% 7.5K
|
Health Technology
|
| O: 0.61%
H: 20.12%
C: 13.41%
disease treatment potential
Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Published: 2020-12-03 (Crawled : 15:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.07%
H: 1.04%
C: 0.65%
cancer fda lung cancer approval treatment application
FDA Clears Rezolute’s IND Application for RZ402RZ402 is an orally available plasma kallikrein inhibitor in development for the treatment of diabetic macular edema
Published: 2020-12-03 (Crawled : 15:00) - biospace.com/
RZLT 4 | $2.91 1.75% 1.72% 340K
|
Technology Services
|
| O: -6.41%
H: 15.07%
C: 15.01%
fda macular diabetic treatment diabetes fda clearance
Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis
Published: 2020-12-03 (Crawled : 12:01) - globenewswire.com
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: -0.6%
H: 4.0%
C: 0.4%
trial treatment phase 2 psoriasis enroll
EyePoint Pharmaceuticals Reports Positive Results from GLP Toxicology Study of EYP-1901, a Potential Six-month Treatment of Wet Age-related Macular Degeneration
Published: 2020-12-03 (Crawled : 12:01) - globenewswire.com
EYPT | News | $16.47 -6.26% -6.68% 1.1M
|
Health Technology
|
| O: -1.89%
H: 3.81%
C: -1.1%
positive results positive results eye macular treatment potential
Aquestive Therapeutics Files IND for Pharmacokinetic Clinical Trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment
Published: 2020-06-29 (Crawled : 09:08) - globenewswire.com
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: 1.79%
H: 0.66%
C: -1.95%
liver trial treatment
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis
Published: 2020-08-10 (Crawled : 09:08) - globenewswire.com
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: 2.23%
H: 10.58%
C: 8.09%
fda liver treatment fast track fda fast track fast track designation designation
Aquestive Therapeutics Initiates Phase 1 Pharmacokinetic Trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) In Development for Treatment of Allergic Reactions Including Anaphylaxis
Published: 2020-08-20 (Crawled : 09:08) - globenewswire.com
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: 0.24%
H: 8.88%
C: 4.44%
liver trial treatment phase 3 phase 1 phase 2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.